Last updated: February 19, 2026
Ipratropium bromide is a short-acting anticholinergic agent used primarily in respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Multiple manufacturers supply this active pharmaceutical ingredient (API), either as bulk API or finished dosage forms.
Major API Suppliers
| Supplier |
Country |
Production Capacity |
Certification |
Notes |
| Cipla Ltd. |
India |
Estimated 10 tons/year |
ISO 9001, GMP |
One of the largest API producers for respiratory drugs. |
| Sipra Pharma |
India |
Estimated 5 tons/year |
GMP |
Supplies globally, focuses on respiratory APIs. |
| Aurobondo Pharma |
India |
Estimated 7 tons/year |
WHO-GMP |
Supplies both generic drugs and APIs. |
| Sanofi (Sanofi-Aventis) |
France |
Confidential |
GMP |
Produces inhalation products, including APIs. |
| Teva Pharmaceutical Industries |
Israel |
Confidential |
GMP |
Supplies respiratory APIs and formulations. |
Finished Dosage Form Suppliers
| Company |
Country |
Formulations Available |
Certification |
Notes |
| Teva Pharmaceuticals |
Israel |
Inhalers, nebulizers |
GMP, ISO 9001 |
One of the largest providers of inhalable medications worldwide. |
| Boehringer Ingelheim |
Germany |
Combination inhalers |
GMP |
Manufactures inhalers with ipratropium bromide as core ingredient. |
| Mylan |
USA |
Metered-dose inhalers (MDIs) |
GMP |
Provides generic inhalers containing ipratropium bromide. |
| Cipla |
India |
MDIs, nebulizer solutions |
GMP |
Exclusive rights to some formulations for certain markets. |
Regulatory & Certification Status
- GMP Compliance: Most suppliers hold Good Manufacturing Practice (GMP) certification, essential for API and drug production.
- WHO-GMP: Some Indian suppliers possess WHO-GMP certification, indicating compliance with international standards.
- FDA Approval: Several suppliers (e.g., Mylan, Teva) are approved for export to the United States.
Market Dynamics & Supply Chain Considerations
- India and China dominate the API production market for ipratropium bromide, due to lower manufacturing costs.
- European and U.S. companies primarily focus on finished formulations, with some API production to support local manufacturing.
- Supply chain disruptions can occur due to regulatory hurdles, capacity constraints, or geopolitical issues.
Key Drivers of Supply
- Patent Status: Ipratropium bromide is off-patent, enabling multiple manufacturers to produce generics.
- Regulatory Approvals: Suppliers with WHO-GMP, US FDA, or European EMA approvals facilitate entry into regulated markets.
- Production Capacity: Capacity varies among suppliers, influencing supply security for global markets.
Strategic Considerations
- Buyers should evaluate supplier certifications and capacity when securing supply.
- Diversification reduces risk of shortages due to geopolitical or regulatory issues.
- Long-term agreements and quality audits are critical for consistent supply, especially in regulated markets.
Summary
The primary API suppliers for ipratropium bromide are companies based mainly in India, with additional sources in Europe and Israel. Finished formulations are concentrated among larger pharmaceutical firms with established inhalation product lines in North America, Europe, and Asia. Supply chains are influenced by manufacturing capacity, regulatory compliance, and geopolitical factors.
Key Takeaways
- India dominates the API production market, with companies like Cipla, Aurobindo, and Sipra.
- Major finished formulation producers include Teva, Boehringer Ingelheim, and Mylan.
- Certification standards such as GMP and WHO-GMP are critical indicators of supply quality.
- Supply security depends on diversified sourcing and understanding regional regulatory landscapes.
- Capacity constraints and geopolitical events can impact supply stability.
FAQs
1. Are there restricted sources for ipratropium bromide API?
Most approved API suppliers hold GMP certifications. Restricted sources typically include unverified or uncertified manufacturers, which pose regulatory and quality risks.
2. What are the leading countries supplying ipratropium bromide?
India supplies the majority of API, followed by China. Finished formulations are supplied from multiple countries, including Germany, Israel, and the U.S.
3. How does patent status influence supplier options?
Ipratropium bromide is off-patent, allowing multiple suppliers to produce generics, increasing market competition and supply options.
4. What are key quality indicators for suppliers?
Certifications like GMP, WHO-GMP, and regulatory approvals from authorities such as the FDA or EMA are critical indicators.
5. Is there local sourcing for North American or European markets?
Yes, companies like Teva (Israel) and Boehringer Ingelheim (Germany) produce finished inhalation products locally or regionally, while API remains predominantly sourced from India and China.
References
- API supplier market reports. (2022). Pharmaceutical Market Intelligence.
- International GMP Certificate Database. (2023). World Health Organization.
- Regulatory approvals databank. (2023). U.S. Food & Drug Administration.
- Industry analysis report: respiratory APIs. (2022). Global Industry Analysts.
- Patent and exclusivity data. (2023). U.S. Patent and Trademark Office.
